  |
 |
|
    |
|
|
|
|
      
|
|
Background
The NBA has successfully concluded the tender process for the supply of a number of imported plasma and recombinant products, to replace the contracts for these products which expire on 30 June 2011.
Media Release:
PDF Document 
| RTF Document 
These products are used to treat patients with bleeding disorders, patients with Protein C deficiency, and women requiring intravenous anti-Rh(D) treatment. These products are not manufactured in Australia.
The outcome of the tender gives Australian patients funded access to products equivalent to that available in other parts of the world at a very competitive price and has been highly successful at ensuring a secure supply of essential products for haemophilia patients. The effect on the implementation of these arrangements is expected to reduce the cost of haemophilia treatment in Australia between $10m and $30m per year over a three year period.
What will change?
As a result of the tender, there will be a change in the brand of several products available free of charge under the National Blood Arrangements:
The details of the new supply arrangements for these imported products compared to previous arrangements are summarised below – Copies of the contracts will be made available on the website at a later date.
Imported Product |
Previous Arrangements |
New Arrangements from 1 July 2011 |
rFVIII |
Advate and Recombinate (Baxter) |
Not available after a transition period |
Xyntha (Pfizer) |
Xyntha (Pfizer) |
|
|
Kogenate FS (Bayer) |
|
rFIX |
BeneFIX (Pfizer) |
BeneFIX (Pfizer) |
APCC |
FEIBA (Baxter) |
FEIBA (Baxter) |
Anti-Rh(D) |
WinRho (Baxter) |
Rhophylac (CSL) |
Protein C |
Ceprotin (Baxter) |
Ceprotin (Baxter) |
pdFVII |
Plasma Derived Factor VII(Baxter)# |
Plasma Derived Factor VII(Baxter) |
pdFXI |
BPL Factor XI and LFB Hemoleven (CSL)# |
|
pdFXIII |
Fibrogammin P (CSL)# |
Fibrogammin P (CSL) |
# - Provided under ad hoc arrangements to meet clinical requirements. Please note, CSL will continue to supply pdFXI on an ad hoc basis.
How will the product changes be managed?
rFVIII
Consultations have been undertaken between AHCDO, HFA, AHNG, NBA, and the suppliers to design arrangements that ensure that appropriate timing and patient/clinician information requirements are addressed. A set of transition principles (PDF Document | RTF Document ) have been agreed to guide the process.
These arrangements will guide the transitioning of all relevant patients at the earliest convenient and clinically appropriate time, with clinical oversight and the appropriate and efficient use of existing Advate and Recombinate stock.
If you currently use Advate or Recombinate, your Haemophilia Treatment Centre or treating clinician will contact you from 1 July 2011 to discuss the products and develop a plan to switch to either Kogenate FS or Xyntha.
Your transition to one of the two other products should occur at the earliest convenient opportunity for you and your treating clinician and HTC. This will take into account the need to schedule clinical consultations and a plan to use your supplies of Advate or Recombinate so that is not wasted. This is expected to take no more than six months for most patients.
More information on what the outcome of the tender means for you can be found in:
| RTF Document | RTF Document
Anti-Rh(D)
Imported anti-RhD is used in Australia to complement domestic supply and where intravenous treatment is required. The previously imported product, WinRho is no longer available and the tender has selected a new product, Rhophylac. Rhophylac is supplied as a 1500IU and is presented in a ready to use prefilled syringe.
Feedback arrangements
The NBA contracts with suppliers require the suppliers to demonstrate to the NBA how they have responded to customer feedback. Patients should discuss any concerns or views they have with their HTC’s.
Feedback | Privacy | Copyright | Disclaimer | Contact Us
This page last modified on June 6, 2011New Blood Processing Centre opened by the Parliamentary Secretary
RFT 03-2012 - Review of Blood Sector Risk Management
Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg)
Review of the authorisation and clinical governance framework for intravenous immunoglobulin
IVIg Review Survey: Have Your Say!
